- Conditions
- Skin Cancer, Non-Melanoma
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 379
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, incomplete Freund's adjuvant, interleukin-2 gene, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy
- Biological · Other · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)
- Interventions
- Nicotinamide, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
- Interventions
- [203Pb]VMT01, [212Pb]VMT01, Nivolumab
- Drug
- Lead sponsor
- Perspective Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 16
- States / cities
- Orange, California • Jacksonville, Florida • Miami, Florida + 12 more
- Conditions
- Kidney Cancer, Melanoma (Skin)
- Interventions
- denileukin diftitox
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Malignant Skin Melanoma T0, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Interventions
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Device
- Lead sponsor
- Skin Analytics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,111 participants
- Timeline
- 2022
- U.S. locations
- 10
- States / cities
- Redwood City, California • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, gp100-fowlpox vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, filgrastim, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration
- Other · Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Melanoma
- Interventions
- Reading materials and discussions, Questionnaires
- Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, indomethacin
- Biological · Drug
- Lead sponsor
- St. Luke's Medical Center
- Other
- Eligibility
- 17 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2004
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
- Drug · Radiation · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cutaneous Malignant Melanoma, Renal Cell Cancer, Urothelial Cancer of Renal Pelvis
- Interventions
- Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy
- Radiation · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Melanoma (Skin)
- Interventions
- dasatinib
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 153
- States / cities
- Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more
- Conditions
- Melanoma (Skin)
- Interventions
- Detox-B adjuvant, verteporfin
- Biological · Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Aventura, Florida • Miami Beach, Florida + 3 more
- Conditions
- Melanoma (Skin)
- Interventions
- therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion
- Biological · Genetic · Drug + 1 more
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
- Interventions
- Secretin, MRI, Tumor marker gene test with CA19-9
- Drug · Diagnostic Test · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2029
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
- Conditions
- Cancer, Other Than Non-melanoma Skin Cancer
- Interventions
- Mobile Mindfulness Meditation, Mindfulness Coach
- Behavioral
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Honolulu, Hawaii
- Conditions
- Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon gamma
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
- Interventions
- blood and tissue samples, blood and tissue samples
- Diagnostic Test · Other
- Lead sponsor
- Paradigm Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 43 more
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Recombinant Interferon Alfa, Bevacizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
- Interventions
- LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolumab and relatlimab), Immunotherapy (ipilimumab and nivolumab)
- Biological · Drug
- Lead sponsor
- Linnaeus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 9
- States / cities
- Newport Beach, California • San Francisco, California • Stanford, California + 6 more
- Conditions
- Non-Melanoma Skin Cancer
- Interventions
- UV Counseling
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado